Karyopharm Therap (KPTI) Misses Q2 EPS by 52c

Karyopharm Therap (NASDAQ: KPTI) reported Q2 EPS of ($1.02), $0.52 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $21 thousand versus the consensus estimate of $150 thousand.

For earnings history and earnings-related data on Karyopharm Therap (KPTI) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Nike dips as BofA downgrades stock on longer-than-expected turnaround
• KeyBanc Reiterates Overweight Rating on Darden Restaurants (DRI)